Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2315 | Meditation (1 x 20-minute guided audio training) Wiki | 0.50 |
| drug4032 | Tocilizumab Injection Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D010148 | Pain, Intractable NIH | 0.71 |
| D002925 | Ciliary Motility Disorders NIH | 0.71 |
| D020820 | Dyskinesias NIH | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012164 | Asterixis HPO | 0.71 |
| HP:0012265 | Ciliary dyskinesia HPO | 0.71 |
| HP:0012532 | Chronic pain HPO | 0.20 |
Navigate: Correlations HPO
There are 2 clinical trials
In this study, defined cases of COVID-19 with mild, moderate or severe pneumonia will be treated with standard treatment regimens in combination with IV injection of Deferoxamine. Improvement in clinical, laboratory and radiological manifestations will be evaluated in treated patient compared to control group.
Description: All cause of death
Measure: Mortality rate Time: up to 20 daysDescription: Mild, Moderate or Severe
Measure: change in patients clinical manifestation Time: up to 20 daysDescription: days
Measure: Length of hospitalization Time: up to 20 daysAssessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, associated with standards treatments in COVID-19 (+) patients, Hospitalized In Intensive care in Tunisia. Multicentric, comparative, randomized study.
Description: Evaluate the mortality rate at 90 days. Evaluate the Intensive Care Unit (ICU) and Hospital Mortality rate at day 90 with date and cause of death (if applicable)
Measure: the mortality rate Time: 90 dayAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports